210 related articles for article (PubMed ID: 32711296)
1. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.
Mallucci G; Zito A; Fabbro BD; Bergamaschi R
Mult Scler Relat Disord; 2020 Oct; 45():102414. PubMed ID: 32711296
[No Abstract] [Full Text] [Related]
2. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Barzegar M; Mirmosayyeb O; Nehzat N; Sarrafi R; Khorvash F; Maghzi AH; Shaygannejad V
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32371550
[No Abstract] [Full Text] [Related]
3. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
4. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
5. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
6. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
7. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Foerch C; Friedauer L; Bauer B; Wolf T; Adam EH
Mult Scler Relat Disord; 2020 Jul; 42():102180. PubMed ID: 32408155
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
Amor S; Baker D; Khoury SJ; Schmierer K; Giovanonni G
Ann Neurol; 2020 Jun; 87(6):794-797. PubMed ID: 32383812
[No Abstract] [Full Text] [Related]
9. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
[No Abstract] [Full Text] [Related]
11. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.
Valero-López G; Carreón-Guarnizo E; Hernández-Clares R; Iniesta-Martínez F; Jiménez-Veiga J; Moreno-Docon A; Iborra-Bendicho MA; Aznar-Robles E; Hellín-Gil MF; Morales-Ortiz A; Meca-Lallana JE
Neurologia (Engl Ed); 2020; 35(6):357-362. PubMed ID: 32591152
[TBL] [Abstract][Full Text] [Related]
12. First motor seizure as presenting symptom of SARS-CoV-2 infection.
Fasano A; Cavallieri F; Canali E; Valzania F
Neurol Sci; 2020 Jul; 41(7):1651-1653. PubMed ID: 32417987
[No Abstract] [Full Text] [Related]
13. SARS-CoV-2 infection in children with febrile neutropenia.
Flores V; Miranda R; Merino L; González C; Serrano C; Solano M; Herrera J; González P; Ruiz G; Saldaña R; Cárdenas A; Chávez-Aguilar LA
Ann Hematol; 2020 Aug; 99(8):1941-1942. PubMed ID: 32529285
[No Abstract] [Full Text] [Related]
14. An Italian programme for COVID-19 infection in multiple sclerosis.
Sormani MP;
Lancet Neurol; 2020 Jun; 19(6):481-482. PubMed ID: 32359409
[No Abstract] [Full Text] [Related]
15. Silencing of immune activation with methotrexate in patients with COVID-19.
Safavi F; Nath A
J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659
[No Abstract] [Full Text] [Related]
16. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
17. Long lasting hypercoagulability after subclinical COVID-19.
Ferroli P; Villa C; Ciuffi A; Gubertini G; Broggi M
J Thromb Thrombolysis; 2020 Nov; 50(4):822-824. PubMed ID: 32757154
[No Abstract] [Full Text] [Related]
18. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
19. Immunosuppression in hematological cancer patients with Covid-19 -Uncomplicated infections but delayed viral clearance?
Boyd K; Parcell B; Tauro S
Leuk Res; 2020 Sep; 96():106407. PubMed ID: 32652329
[No Abstract] [Full Text] [Related]
20. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
